Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia

Haematologica

Volumn 83, Issue 6, 1998, Pages 496-501

  Mazza, Patrizio ^a,c   Amurri, Barbara ^a   Lazzari, Grazia ^a   Masi, Concetta ^a   Palazzo, Giulia ^a   Spartera, Maria Ada ^b   Giua, Roberto ^b   Sebastio, Anna Maria ^b   Suma, Vincenzo ^b   De Marco, Sebastiano ^b   Semeraro, Francesco ^b   Moscogiuri, Rossella ^b  

^a Centro per le Microcitemie

^b Ospedale SS Annunziata   (Italy)

^c Ospedale Nord   (Italy)

Author keywords

Desferrioxamine; Oral iron chelation; Siderosis; Thalassemia

Indexed keywords

CHELATING AGENT; DEFERIPRONE; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; CHELATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SIDEROSIS; THALASSEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOPSY; FEMALE; HUMANS; IRON CHELATING AGENTS; LIVER; MALE; PYRIDONES; THALASSEMIA; TREATMENT OUTCOME;

EID: 0031873538     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassemia major. Lancet 1989; ii:27-30.
2. Olivieri NF, Nathan DG, MacMillan JH. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331:574-8.
3. Al-Refaie FN, Hoffbrand AV. Oral iron chelation therapy. Rec Adv Haematol 1993;7:185-216.
4. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br J Haematol 1995; 91:224-9.
5. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)[abstract]. Blood 1997; (suppl 90):1161a.
6. Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica 1995; 80:398-404.
7. Sheuer PJ, William R, Muir AR. Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacterial 1962; 84:53-64.
8. Barry M, Flynn D, Letsky E, Risdon RA. Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J 1974; 2:16-20.
9. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76:435-44.
10. Argawal MB, Gupte SS, Viswanathan C, et al. Long-term assessement of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 1992; 82:460-6.
11. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 79:2741-8.
12. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332:918-22.
13. Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Al-Refaie FN, Wonke B. Results of long-term deferiprone (L1) therapy. A report by the international study group on oral iron chelators [abstract]. Blood 1994; 84(suppl.):1012.
14. Olivieri NF, Sher GD, McKinnon JA, et al. The first prospective randomized trial of subcutaneous Deferoxamine and the orally active iron chelating agent L1 [abstract]. Blood 1994; 84(suppl.)1436.